TYK349: Difference between revisions
m 1 revision imported |
m Text replacement - "<p style="text-align: center;"> About Test Your Knowledge</p>" to "<p style="text-align: center;"> About Test Your Knowledge</p> Category:TYK" |
||
| Line 27: | Line 27: | ||
<p style="text-align: center;">[[TYK348|<Prev Question]] --- [[TYK350|Next Question>]]</p> | <p style="text-align: center;">[[TYK348|<Prev Question]] --- [[TYK350|Next Question>]]</p> | ||
<p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | <p style="text-align: center;">[[TYK About | About Test Your Knowledge]]</p> | ||
[[Category:TYK]] | |||
Latest revision as of 02:22, 25 September 2026
FDA approved indications for the use of recombinant VIIa include which of the following:
a) Use in patients with severe blood loss associated with trauma.
b) Use in patients with congenital factor VII deficiency.
c) Use in patients with intracerebral hemorrhage.
d) Use in patients undergoing open cardiac surgery requiring cardiopulmonary bypass.
Click for Answer
Answer
Answer b. Currently the only FDA approved indications include use in patients with congenital factor VII deficiency and in patients with hemophilia.
Notes
- This question originally printed in the Pediatric Anesthesiology Review Topics kindle book series, and appears courtesy of Naerthwyn Press, LLC.